Work

The ExTINGUISH Trial: A Phase-2B Randomized Placebo-Controlled Trial of Inebilizumab in Anti-NMDA Receptor Encephalitis (P5-1.004)

Year: 2022

Type: article

Study design: Clinical Trial

Source: Neurology

DOI: 10.1212/wnl.98.18_supplement.1651

Authors: Gregory Day, Maarten Titulaer, Ka-Ho Wong, James Torner, Merit Cudkowicz, Christopher Coffey, Codrin Lungu, Eric Klawiter, J. Robert Singleton, Dana Mitchell, Janel Fedler, Dixie Ecklund, David Klements, Michele Costigan, Stacey Clardy

Institutions: Mayo Clinic, Erasmus MC, University of Utah, University of Iowa, Massachusetts General Hospital, National Institutes of Health, National Institute of Neurological Disorders and Stroke, Indiana University School of Medicine, Indiana University

Language: English

Topic: Autoimmune Neurological Disorders and Treatments

Subfield: Neurology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4389367979

FWCI: 0.789

Cites:

Cited by: 7

Related to: 10